Trials / Completed
CompletedNCT05810558
Impact of Glycine Therapy on Peri-implant Mucositis
Impact of Glycine-augmented Prophylaxis on Resolution of Peri-implant Mucositis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Ohio State University · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to determine the impact of glycine powder air-abrasive debridement (GPAD) on the microbiology of the tissues surrounding dental implants with health and inflammation (peri-implant mucositis).
Detailed description
Peri-implant mucositis, or the infection of the gingival tissues surrounding a dental implant, and peri-implantitis, or the infection of the gingival tissue surrounding a dental implant with bone loss, can lead to the failure and eventual loss of dental implants. The prevalence of peri-implant mucositis ranges from 30.7-43% and the prevalence of peri-implantitis ranges from 9.6-22% with non-smokers. Traditional treatment of this disease has been through biofilm removal using ultrasonic instrumentation. Glycine is a non-essential amino acid that possesses an anti-inflammatory, immunomodulary, and a cytoprotective effect. The goal of this investigation is to examine the impact of glycine-augmented biofilm removal on resolution of peri-implant mucositis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | glycine powder air-powered debridement | The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds. |
| PROCEDURE | Ultrasonic instrumentation | The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste |
Timeline
- Start date
- 2016-06-16
- Primary completion
- 2017-09-30
- Completion
- 2020-12-30
- First posted
- 2023-04-12
- Last updated
- 2023-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05810558. Inclusion in this directory is not an endorsement.